Side-by-side · Research reference
HumaninvsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/52 cited
BFDA-ApprovedFlagship14/45 cited
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
Humanin
Liraglutide
Primary target
Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022Lue 2021
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Glucose-dependent insulin release preserves physiological feedback
Origin
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Antibody development
Not reported in animal models
—
02Dosage Protocols
Parameter
Humanin
Liraglutide
Standard experimental dose (HNG)
4 mg/kg IP (rat)
Most common dose in rodent models.
—
Ex vivo bone culture
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
—
Frequency
Daily (IP)
Once daily, same time each day
Duration
8–12 weeks in animal studies
Indefinite for chronic indication
Evidence basis
Animal models (rat, mouse)Huang 2025El 2022Velentza 2024
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Human data
None — no clinical trials reported
—
Analog (HNG)
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
—
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-filled commercial pen (no reconstitution)
Timing
—
Any time of day; consistent
03Metabolic / Fat Loss Evidence
Parameter
Humanin
Liraglutide
Direct fat loss evidence
None
—
Mechanism overlap
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
—
04Side Effects & Safety
Parameter
Humanin
Liraglutide
Animal model safety
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
—
Human safety data
None — no clinical trials
—
Theoretical fibrillation risk
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
—
Injection site reaction
Not reported in animal studies (IP route)
—
Reproductive safety
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
—
GI symptoms
—
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
Humanin
- ·Unknown — no human data
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
Humanin
Liraglutide
1. Route (experimental)
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
Commercial pre-filled pen, no reconstitution required.
2. Reconstitution
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Daily administration in animal studies. Optimal timing not characterized.
Once daily, same time each day. Take with or without food.
4. Storage
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Human use
No FDA approval, no IND, no clinical trials. Experimental research tool only.
Pen-supplied 32G needle.
06Stack Synergy
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling
Liraglutide
— no documented stacks